Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Extensively drug-resistant tuberculosis: a new face to an old pathogen.

Literature DB >> 19630575

Extensively drug-resistant tuberculosis: a new face to an old pathogen.

Abstract

The presence and consequences of resistance to drugs used for the treatment of tuberculosis have long been neglected. The recent detection and recognition of widespread multiple-drug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis have raised interest and concern among clinicians and public health authorities globally. In this article, we describe the current global status of drug-resistant tuberculosis. We discuss the development of resistance, current management, and strategies for control.

Entities: Chemical Disease Gene Species

Mesh：

Year: 2009 PMID： 19630575 PMCID： PMC3013225 DOI： 10.1146/annurev.med.60.053107.103955

Source DB: PubMed Journal: Annu Rev Med ISSN： 0066-4219 Impact factor: 13.739

48 in total

1. Managing multiple and extensively drug-resistant tuberculosis and HIV.

Authors: Nesri Padayatchi; Gerald Friedland
Journal: Expert Opin Pharmacother Date: 2007-06 Impact factor: 3.889

2. STREPTOMYCIN treatment of pulmonary tuberculosis.

Authors:
Journal: Br Med J Date: 1948-10-30

3. Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors: Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245

Review 4. Treatment Options for HIV-Associated Tuberculosis.

Authors: Philip Chukwuka Onyebujoh; Isabela Ribeiro; Christopher Curtis Whalen
Journal: J Infect Dis Date: 2007-08-15 Impact factor: 5.226

5. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.

Authors: Hye-Ryoun Kim; Seung Sik Hwang; Hyun Ji Kim; Sang Min Lee; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal: Clin Infect Dis Date: 2007-10-15 Impact factor: 9.079

6. Decentralising tuberculosis services from county tuberculosis dispensaries to township hospitals in China: an intervention study.

Authors: X Wei; X Liang; F Liu; J D Walley; B Dong
Journal: Int J Tuberc Lung Dis Date: 2008-05 Impact factor: 2.373

7. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

Authors: Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer
Journal: N Engl J Med Date: 2003-01-09 Impact factor: 91.245

8. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS.

Authors: M Lutfey; P Della-Latta; V Kapur; L A Palumbo; D Gurner; G Stotzky; K Brudney; J Dobkin; A Moss; J M Musser; B N Kreiswirth
Journal: Am J Respir Crit Care Med Date: 1996-02 Impact factor: 21.405

Review 9. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.

Authors: Helen McIlleron; Graeme Meintjes; William J Burman; Gary Maartens
Journal: J Infect Dis Date: 2007-08-15 Impact factor: 5.226

10. Randomized trials to optimize treatment of multidrug-resistant tuberculosis.

Authors: Carole D Mitnick; Kenneth G Castro; Mark Harrington; Leonard V Sacks; William Burman
Journal: PLoS Med Date: 2007-11-06 Impact factor: 11.069

22 in total

1. Protein-protein interaction networks suggest different targets have different propensities for triggering drug resistance.

Authors: Jyothi Padiadpu; Rohit Vashisht; Nagasuma Chandra
Journal: Syst Synth Biol Date: 2011-02-20

2. New antibacterials?

Authors: Kevin B Laupland; David N Fisman
Journal: Can J Infect Dis Med Microbiol Date: 2010 Impact factor: 2.471

Review 3. Targeting the "cytokine storm" for therapeutic benefit.

Authors: Riccardo V D'Elia; Kate Harrison; Petra C Oyston; Roman A Lukaszewski; Graeme C Clark
Journal: Clin Vaccine Immunol Date: 2013-01-02

4. Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design.

Authors: Wook Lee; Sylvia R Luckner; Caroline Kisker; Peter J Tonge; Bernd Engels
Journal: Biochemistry Date: 2011-06-07 Impact factor: 3.162

5. Immune regulation of miR-30 on the Mycobacterium tuberculosis-induced TLR/MyD88 signaling pathway in THP-1 cells.

Authors: Yuqing Wu; Qi Sun; Liang Dai
Journal: Exp Ther Med Date: 2017-08-02 Impact factor: 2.447

6. Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis.

Authors: Thulasi Warrier; Marielle Tropis; Jim Werngren; Anne Diehl; Martin Gengenbacher; Brigitte Schlegel; Markus Schade; Hartmut Oschkinat; Mamadou Daffe; Sven Hoffner; Ali Nasser Eddine; Stefan H E Kaufmann
Journal: Antimicrob Agents Chemother Date: 2012-01-30 Impact factor: 5.191